EPP Pricing Events

Sarah Pitluck

Head,Global Pricing and Reimbursement - SPARK THERAPEUTICS


Ms. Pitluck is the Head of Global Pricing & Reimbursement (P&R) at Spark Therapeutics. In her current role, Ms. Pitluck priced the first US Food and Drug Administration-approved gene therapy for a genetic disease, LUXTURNA® (voretigene neparvovec-rzyl). She is now working to ensure market access for all US patients in need of LUXTURNA including completing the first Centers for Medicare & Medicaid Services (CMS) demonstration project to provide alternate payment options and value-based arrangements for single-administration therapies like LUXTURNA. Prior to joining Spark, she was the Executive Director for Global P&R at Alexion Pharmaceuticals, leading all global P&R efforts, including dossier preparation and negotiations for Alexion globally. She was formerly the Director of Genentech’s Coverage & Reimbursement Policy and responsible for all US public payer policy and reimbursement issues for Genentech’s products. She also worked at healthcare consulting companies including Avalere Health and Covance Health Economics and Outcomes Services Inc., focusing on policy and reimbursement analyses for a variety of pharmaceutical, biotechnology, and medical device products related to care settings and disease areas. Ms. Pitluck received her Masters of Science at the London School of Economics and Political Science.